SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC)

MS Michel; W Vervenne; M de Santis; LF von Weikersthal; PJ Goebell; J Lerchenmueller; U Zimmermann; MMEM Bos; W Freier; S Schirrmacher-Memmel; MD Staehler; Sascha Pahernik; M Los; M Schenck; A Florcken; C Van Arkel; K Hauswald; M Indorf; D Gottstein; C Eichelberg

SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC)

MS Michel, W Vervenne, M de Santis, LF von Weikersthal, PJ Goebell, J Lerchenmueller, U Zimmermann, MMEM Bos, W Freier, S Schirrmacher-Memmel, MD Staehler, Sascha Pahernik, M Los, M Schenck, A Florcken, C Van Arkel, K Hauswald, M Indorf, D Gottstein, C Eichelberg

Department of Urology

Research output: Contribution to journal › published Abstract (Journal) › peer-review

28 Citations (Web of Science)

Original language	English
Journal	JOURNAL OF CLINICAL ONCOLOGY
Volume	32
Issue number	4
Publication status	Published - 2014
Event	Genitourinary Cancers Symposium - San Francisco, CA Duration: 30 Jan 2014 → 1 Feb 2014

Cite this

Michel, MS., Vervenne, W., de Santis, M., von Weikersthal, LF., Goebell, PJ., Lerchenmueller, J., Zimmermann, U., Bos, MMEM., Freier, W., Schirrmacher-Memmel, S., Staehler, MD., Pahernik, S., Los, M., Schenck, M., Florcken, A., Van Arkel, C., Hauswald, K., Indorf, M., Gottstein, D., & Eichelberg, C. (2014). SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). JOURNAL OF CLINICAL ONCOLOGY , 32(4).

Michel, MS ; Vervenne, W ; de Santis, M et al. / SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). In: JOURNAL OF CLINICAL ONCOLOGY 2014 ; Vol. 32, No. 4.

@article{ae29578897104d4fa117e0ab3a13a11f,

title = "SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC)",

author = "MS Michel and W Vervenne and {de Santis}, M and {von Weikersthal}, LF and PJ Goebell and J Lerchenmueller and U Zimmermann and MMEM Bos and W Freier and S Schirrmacher-Memmel and MD Staehler and Sascha Pahernik and M Los and M Schenck and A Florcken and {Van Arkel}, C and K Hauswald and M Indorf and D Gottstein and C Eichelberg",

year = "2014",

language = "English",

volume = "32",

journal = "JOURNAL OF CLINICAL ONCOLOGY ",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins ",

number = "4",

note = "Genitourinary Cancers Symposium ; Conference date: 30-01-2014 Through 01-02-2014",

}

Michel, MS, Vervenne, W, de Santis, M, von Weikersthal, LF, Goebell, PJ, Lerchenmueller, J, Zimmermann, U, Bos, MMEM, Freier, W, Schirrmacher-Memmel, S, Staehler, MD, Pahernik, S, Los, M, Schenck, M, Florcken, A, Van Arkel, C, Hauswald, K, Indorf, M, Gottstein, D & Eichelberg, C 2014, 'SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC)', JOURNAL OF CLINICAL ONCOLOGY , vol. 32, no. 4.

SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). / Michel, MS; Vervenne, W; de Santis, M et al.
In: JOURNAL OF CLINICAL ONCOLOGY , Vol. 32, No. 4, 2014.

Research output: Contribution to journal › published Abstract (Journal) › peer-review

TY - JOUR

T1 - SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC)

AU - Michel, MS

AU - Vervenne, W

AU - de Santis, M

AU - von Weikersthal, LF

AU - Goebell, PJ

AU - Lerchenmueller, J

AU - Zimmermann, U

AU - Bos, MMEM

AU - Freier, W

AU - Schirrmacher-Memmel, S

AU - Staehler, MD

AU - Pahernik, Sascha

AU - Los, M

AU - Schenck, M

AU - Florcken, A

AU - Van Arkel, C

AU - Hauswald, K

AU - Indorf, M

AU - Gottstein, D

AU - Eichelberg, C

PY - 2014

Y1 - 2014

M3 - published Abstract (Journal)

SN - 0732-183X

VL - 32

JO - JOURNAL OF CLINICAL ONCOLOGY

JF - JOURNAL OF CLINICAL ONCOLOGY

IS - 4

T2 - Genitourinary Cancers Symposium

Y2 - 30 January 2014 through 1 February 2014

ER -

Michel MS, Vervenne W, de Santis M, von Weikersthal LF, Goebell PJ, Lerchenmueller J et al. SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). JOURNAL OF CLINICAL ONCOLOGY . 2014;32(4).